arrow
Return

Nanophotonics Enable Targeted Photothermal Silencing of Nociceptor Neurons

delete2022-02-23
delete6
PRE
AI
K
Katiane Roversi
M
Maryam Tabatabaei
N
Nicolas Desjardins‐Lecavalier
M
Mohammad Balood
T
Théo Crosson
S
Santiago Costantino
M
May Griffith
S
Sébastien Talbot *
C
Christos Boutopoulos *
DOI:10.1002/smll.202103364delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
The sensory nervous and immune systems work in concert to preserve homeostasis. While this endogenous interplay protects from danger, it may drive chronic pathologies. Currently, genetic engineering of neurons remains the primary approach to interfere selectively with this potentially deleterious interplay. However, such manipulations are not feasible in a clinical setting. Here, this work reports a nanotechnology-enabled concept to silence subsets of unmodified nociceptor neurons that exploits their ability to respond to heat via the transient receptor potential vanilloid type 1 (TRPV1) channel. This strategy uses laser stimulation of antibody-coated gold nanoparticles to heat-activate TRPV1, turning this channel into a cell-specific drug-entry port. This delivery method allows transport of a charged cationic derivative of an N-type calcium channel blocker (CNCB-2) into targeted sensory fibers. CNCB-2 delivery blocks neuronal calcium currents and neuropeptides release, resulting in targeted silencing of nociceptors. Finally, this work demonstrates the ability of the approach to probe neuro-immune crosstalk by targeting cytokine-responsive nociceptors and by successfully preventing nociceptor-induced CD8(+) T-cells polarization. Overall, this work constitutes the first demonstration of targeted silencing of nociceptor neuron subsets without requiring genetic modification, establishing a strategy for interfering with deleterious neuro-immune interplays.
Keywords:
functionalized gold nanoparticles
nanophotonics
nociceptor neurons
N-type calcium channel blocker (CNCB-2)
photothermal silencing
targeted drug delivery
transient receptor potential vanilloid type 1 (TRPV1)

Journal

Small cover
Small
IF:
12.1
Papers:
3.0W
Citations:
16.4W

Organization

U
universite de montreal
Scholars:
4.6W
Papers: 3.8W
Citations: 46